MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

MDT

95.97

-0.18%↓

136.48

+0.21%↑

VEEV

219.11

-1.79%↓

HQY

91.01

-0.55%↓

PHR.US

16.33

-3.37%↓

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Open

8.36 -7.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.18

Max

8.91

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+56.92% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	61M 648M
Vorige openingsprijs	15.47
Vorige sluitingsprijs	8.36

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 dec 2025, 22:20 UTC

Belangrijke Marktbewegers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dec 2025, 17:31 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dec 2025, 16:30 UTC

Belangrijke Marktbewegers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dec 2025, 15:19 UTC

Belangrijke Marktbewegers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dec 2025, 15:17 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dec 2025, 14:37 UTC

Belangrijke Marktbewegers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1 jan 2026, 23:35 UTC

Marktinformatie

Gold Rises Amid Geopolitical Risks -- Market Talk

1 jan 2026, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1 jan 2026, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Sold Stake in JV to Tata Steel

1 jan 2026, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 jan 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

31 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dec 2025, 20:40 UTC

Marktinformatie

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dec 2025, 20:22 UTC

Marktinformatie

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dec 2025, 19:50 UTC

Marktinformatie

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dec 2025, 19:31 UTC

Marktinformatie

Precious Metals Cap Off Record Runs -- Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

31 dec 2025, 18:50 UTC

Marktinformatie

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dec 2025, 17:17 UTC

Marktinformatie

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dec 2025, 17:16 UTC

Belangrijke Marktbewegers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

31 dec 2025, 17:00 UTC

Acquisities, Fusies, Overnames

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dec 2025, 15:57 UTC

Acquisities, Fusies, Overnames

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dec 2025, 15:54 UTC

Marktinformatie

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dec 2025, 15:02 UTC

Belangrijke Marktbewegers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dec 2025, 14:40 UTC

Acquisities, Fusies, Overnames

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dec 2025, 14:20 UTC

Marktinformatie

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dec 2025, 13:46 UTC

Marktinformatie

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

56.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.17 USD 56.92%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.